Stay updated with breaking news from Michiels van. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Patients with previously untreated locally advanced or metastatic urothelial carcinoma experienced favorable progression-free survival, overall survival and objective response rates when treated with Padcev and Keytruda versus chemotherapy. ....
Enfortumab vedotin plus pembrolizumab showed consistent overall survival and progression-free survival benefit in all patients enrolled in EV-302. ....
Concurrent frontline nivolumab and gemcitabine-cisplatin followed by nivolumab maintenance therapy elicited OS and PFS benefits vs gemcitabine-cisplatin alone in patients with previously untreated, metastatic or unresectable urothelial carcinoma. ....
Adding Opdivo to a standard-of-care chemotherapy regimen in patients with unresectable or metastatic urothelial carcinoma improved progression-free and overall survival. ....